Therapeutic approaches targeting tumor vasculature in gastrointestinal cancers

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• Antiangiogenic therapy, particularly anti-vascular endothelial growth factor (VEGF) antibody treatment, is a key strategy for managing various human cancers, including gastrointestinal tumors.
• Resistance to anti-VEGF therapy is a significant clinical challenge, stemming from cancers that do not upregulate VEGF or develop phenotypic resistance to VEGF-targeted agents.
• The precise molecular and cellular mechanisms underlying resistance to VEGF-targeted agents remain incompletely understood.

Purpose of the Study:

• To elucidate the mechanisms of resistance to anti-VEGF antibody therapy in malignancies.
• To identify strategies for improving antiangiogenic regimens to overcome drug resistance.
• To explore the potential of anti-VEGF antibodies in cancer chemoprevention.

Main Methods:

• Review and analysis of existing literature on antiangiogenic therapy resistance.
• Investigation of molecular pathways involved in VEGF signaling and resistance.
• Exploration of preclinical and clinical data regarding anti-VEGF antibody efficacy and resistance.

Main Results:

• Identified two primary reasons for resistance: lack of VEGF upregulation in some advanced colon cancers and acquired phenotypic resistance to VEGF or its receptors post-therapy.
• Highlighted the incomplete understanding of the molecular and cellular mechanisms driving resistance.
• Suggested that improved understanding could lead to better patient selection for VEGF-targeted therapy.

Conclusions:

• Enhanced understanding of resistance mechanisms is crucial for optimizing antiangiogenic therapy and improving patient outcomes.
• Further research into overcoming drug resistance is needed to maximize the benefits of VEGF-targeted treatments.
• Anti-VEGF antibodies hold potential for cancer chemoprevention by inhibiting tumor growth before the angiogenic switch.